The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Identification of Breath Biomarkers in Head and Neck Squamous Cell Carcinoma
Official Title: A Prospective Cohort Study to Determine Specific Volatile Organic Compounds Present in Breath Samples of Patients With Oral Cavity or Oropharyngeal Squamous Cell Carcinoma Using Gas Chromotography-mass Spectrometry
Study ID: NCT02156180
Brief Summary: In this study the Investigators aim to determine specific volatile compounds present in breath samples of patients with oral cavity or oropharyngeal squamous cell carcinoma before and after tumour resection or before and after chemotherapy +/- radiotherapy using gas chromotography-mass spectrometry. The Investigators hypothesize that study participants with a tumour will display a distinct set of volatile organic compounds than can serve as potential cancer biomarkers.
Detailed Description: Head and neck cancer diagnosis is devastating as it frequently disrupts one's ability to communicate, swallow and breathe. Each year, physicians diagnose approximately 650,000 cases of head and neck cancer worldwide. Many people with head and neck cancer have their cancer detected late, and this can result in a poor clinical outcome. One strategy to improve the clinical outcomes for people with a head and neck cancer is to develop a non-invasive screening assay using breath biomarkers. Such a diagnostic tool will identify at-risk individuals early, and potentially offer improved and cost-effective treatment. The idea of using human breath samples to detect cancer began with the observation that dogs can be trained to "sniff out" certain types of cancers from urine and blood. Since then the presence of various volatile organic compounds from many types of cancers, including: lung, skin, breast, prostate, and bladder have been characterized. These studies are ongoing, but promise to revolutionize the way physicians screen cancer in the future. In this pilot study, the Investigators aim to determine specific volatile organic compounds present in breath samples of patients with oral cavity or oropharyngeal cancer before and after tumor resection, or before and after definitive chemotherapy/radiotherapy. As head and neck cancer can result in significant functional deficit, early detection is the key to improving clinical outcome. Much anecdotal evidence exists for the presence of distinct odor emissions from the tumor bed of head and neck cancer patients. Therefore, the identification of specific volatile organic compound to head and neck cancer will undoubtedly lead to a novel, cost-effective screening strategy for early detection of head and neck cancer.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Princess Alexandra Hospital, Brisbane, Queensland, Australia
Name: Jae Lim, Dr
Affiliation: Princess Alexandra Hospital
Role: PRINCIPAL_INVESTIGATOR
Name: Ben Panizza, Assoc Prof
Affiliation: Princess Alexandra Hospital
Role: PRINCIPAL_INVESTIGATOR
Name: Vince Alberts, Mr
Affiliation: Queensland Health Forensic and Scientific Services
Role: PRINCIPAL_INVESTIGATOR
Name: Jeff Herse, Mr
Affiliation: Queensland Health Forensic and Scientific Services
Role: PRINCIPAL_INVESTIGATOR
Name: David Pass, Mr
Affiliation: Queensland Health Forensic and Scientific Services
Role: PRINCIPAL_INVESTIGATOR
Name: Nigel Brown, Dr
Affiliation: Princess Alexandra Hospital
Role: PRINCIPAL_INVESTIGATOR